Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma

Sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Study ID
NCT04440917
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a prospective, open-labelled study to evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the induction treatment of patients with locally advanced head and neck squamous cell carcinoma who were judged surgically unresectable or appropriate for non-surgical definitive therapy. The objective response rate (ORR) and safety will be evaluated as the primary endpoints, the 2-year overall survival (OS) rate and progression free survival (PFS) rate will be the second endpoints.

Key Dates

Start date
Jun 3, 2020
Status verified
Jun 2020
Primary completion
Jun 30, 2022
Completion
Dec 31, 2023

Study Design

Enrollment
32 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Study group
    Inductive therapy with Camrelizumab and Apatinib

Primary Outcome Measure

Objective Response Rate (CR+PR) [ Time Frame: 9 weeks ]

Central Contacts

Related Studies